Hypercholesterolaemia - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Hypercholesterolaemia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hypercholesterolaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Hypercholesterolaemia: Overview
Cholesterol is a component (a lipid or fat) that circulates in the bloodstream which the body uses to construct cells and produce certain substances that it needs. In this respect, its presence is both good and necessary. However, hypercholesterolaemia, or an excessive level or amount of cholesterol in the blood, can be harmful because it causes atheromatous plaques to deposit in the arteries (atherosclerosis). Therefore, it predisposes the development of cardiovascular diseases such as heart attacks, strokes or an insufficient blood supply to the limbs.
The need for treatment to reduce cholesterol levels must be individualised to each person and largely depends on the risk of suffering a cardiovascular event. There are several strategies to reduce cholesterol with medicines. For instance, there are drugs that decrease cholesterol production in the liver or which enable the liver to capture or “clean” more cholesterol from the blood. Statins are the treatment of choice and best-known drug therapy against hypercholesterolaemia. Ezetimibe acts by reducing cholesterol absorption in the intestine. Resins act in the intestine by promoting the elimination of bile which has a very high cholesterol content.
Report Highlights
This segment of the Hypercholesterolaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hypercholesterolaemia Emerging Drugs
It is currently in Phase III stage of development for Hypercholesterolaemia and is being developed by Innovent Biologics.
It is currently in Phase II stage of development for Hypercholesterolaemia and is being developed by Akeso Biopharma.
Further product details are provided in the report..
Hypercholesterolaemia: Therapeutic Assessment
This segment of the report provides insights about the different Hypercholesterolaemia drugs segregated based on following parameters that define the scope of the report, such as:
Hypercholesterolaemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hypercholesterolaemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypercholesterolaemia drugs.
Hypercholesterolaemia Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Hypercholesterolaemia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hypercholesterolaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hypercholesterolaemia: Overview
Cholesterol is a component (a lipid or fat) that circulates in the bloodstream which the body uses to construct cells and produce certain substances that it needs. In this respect, its presence is both good and necessary. However, hypercholesterolaemia, or an excessive level or amount of cholesterol in the blood, can be harmful because it causes atheromatous plaques to deposit in the arteries (atherosclerosis). Therefore, it predisposes the development of cardiovascular diseases such as heart attacks, strokes or an insufficient blood supply to the limbs.
The need for treatment to reduce cholesterol levels must be individualised to each person and largely depends on the risk of suffering a cardiovascular event. There are several strategies to reduce cholesterol with medicines. For instance, there are drugs that decrease cholesterol production in the liver or which enable the liver to capture or “clean” more cholesterol from the blood. Statins are the treatment of choice and best-known drug therapy against hypercholesterolaemia. Ezetimibe acts by reducing cholesterol absorption in the intestine. Resins act in the intestine by promoting the elimination of bile which has a very high cholesterol content.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Hypercholesterolaemia R&D. The therapies under development are focused on novel approaches for Hypercholesterolaemia.
This segment of the Hypercholesterolaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hypercholesterolaemia Emerging Drugs
- IBI306: Innovent Biologics
It is currently in Phase III stage of development for Hypercholesterolaemia and is being developed by Innovent Biologics.
- AK-102: Akeso Biopharma
It is currently in Phase II stage of development for Hypercholesterolaemia and is being developed by Akeso Biopharma.
Further product details are provided in the report..
Hypercholesterolaemia: Therapeutic Assessment
This segment of the report provides insights about the different Hypercholesterolaemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Hypercholesterolaemia
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Hypercholesterolaemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hypercholesterolaemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypercholesterolaemia drugs.
Hypercholesterolaemia Report Insights
- Hypercholesterolaemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Hypercholesterolaemia drugs?
- How many Hypercholesterolaemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Hypercholesterolaemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypercholesterolaemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hypercholesterolaemia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Akeso Biopharma
- LIB Therapeutics
- Innovent Biologics
- Jiangsu HengRui Medicine
- AstraZeneca
- Vaxxinity
- AK102
- IBI306
- Lerodalcibep
- SHR-1209
- AZD8233
- Research programme: PCSK 9 inhibitor vaccine
Introduction
Executive Summary
Hypercholesterolaemia: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Hypercholesterolaemia– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Hypercholesterolaemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Hypercholesterolaemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
IBI306: Innovent Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
AK102: Akeso Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
Research programme: PCSK 9 inhibitor vaccine: Vaxxinity
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Hypercholesterolaemia Key Companies
Hypercholesterolaemia Key Products
Hypercholesterolaemia- Unmet Needs
Hypercholesterolaemia- Market Drivers and Barriers
Hypercholesterolaemia- Future Perspectives and Conclusion
Hypercholesterolaemia Analyst Views
Hypercholesterolaemia Key Companies
Appendix
Executive Summary
Hypercholesterolaemia: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Hypercholesterolaemia– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Hypercholesterolaemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Hypercholesterolaemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
IBI306: Innovent Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
AK102: Akeso Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
Research programme: PCSK 9 inhibitor vaccine: Vaxxinity
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Hypercholesterolaemia Key Companies
Hypercholesterolaemia Key Products
Hypercholesterolaemia- Unmet Needs
Hypercholesterolaemia- Market Drivers and Barriers
Hypercholesterolaemia- Future Perspectives and Conclusion
Hypercholesterolaemia Analyst Views
Hypercholesterolaemia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Hypercholesterolaemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Hypercholesterolaemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Hypercholesterolaemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Hypercholesterolaemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
